These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24188864)

  • 1. Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis.
    Rossi G; Ibba F; Meazzi S; Giordano A; Paltrinieri S
    Vet J; 2014 Jan; 199(1):143-9. PubMed ID: 24188864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
    Paradies P; Sasanelli M; Amato ME; Greco B; De Palo P; Lubas G
    Res Vet Sci; 2012 Oct; 93(2):843-7. PubMed ID: 22296941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
    Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE
    Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
    Saridomichelakis MN; Xenoulis PG; Chatzis MK; Kasabalis D; Steiner JM; Suchodolski JS; Petanides T
    Vet Parasitol; 2013 Oct; 197(1-2):22-8. PubMed ID: 23685064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of domperidone supplementation on short-term changes in C-reactive protein and paraoxonase-1 in dogs with leishmaniasis undergoing meglumine antimoniate and allopurinol therapy.
    Paltrinieri S; Ibba F; Barbè F; Rossi G
    Vet Clin Pathol; 2020 Dec; 49(4):618-623. PubMed ID: 33341970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
    Amusategui I; Sainz A; Tesouro MA
    Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
    [No Abstract]   [Full Text] [Related]  

  • 7. Some remarks about the LeishVet directions for the treatment of canine leishmaniasis.
    Lamothe J
    Vet Parasitol; 2010 May; 169(3-4):416-7; author reply 418-20. PubMed ID: 20106598
    [No Abstract]   [Full Text] [Related]  

  • 8. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
    João A; Pereira MA; Cortes S; Santos-Gomes GM
    J Vet Med A Physiol Pathol Clin Med; 2006 Dec; 53(10):540-5. PubMed ID: 17105576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
    Pardo-Marín L; Martínez-Subiela S; Pastor J; Tvarijonaviciute A; Garcia-Martinez JD; Segarra S; Cerón JJ
    BMC Vet Res; 2017 Jan; 13(1):31. PubMed ID: 28114941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentration of high density lipoproteins (HDLs) in leishmaniotic dogs.
    Ibba F; Rossi G; Meazzi S; Giordano A; Paltrinieri S
    Res Vet Sci; 2015 Feb; 98():89-91. PubMed ID: 25440996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
    Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
    Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol.
    Cortese L; Pelagalli A; Piantedosi D; Mastellone V; Di Loria A; Lombardi P; Ciaramella P; Avallone L
    Vet J; 2008 Sep; 177(3):405-10. PubMed ID: 17629526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study.
    Pierantozzi M; Roura X; Paltrinieri S; Poggi M; Zatelli A
    J Am Anim Hosp Assoc; 2013; 49(4):231-6. PubMed ID: 23690493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical follow-up examination after treatment of canine leishmaniasis.
    Moritz A; Steuber S; Greiner M
    Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
    Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F
    Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment.
    Martínez-Subiela S; Bernal LJ; Cerón JJ
    Am J Vet Res; 2003 Aug; 64(8):1021-6. PubMed ID: 12926596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in serum biomarkers of oxidative stress after treatment for canine leishmaniosis in sick dogs.
    Rubio CP; Martinez-Subiela S; Tvarijonaviciute A; Hernández-Ruiz J; Pardo-Marin L; Segarra S; Ceron JJ
    Comp Immunol Microbiol Infect Dis; 2016 Dec; 49():51-57. PubMed ID: 27865264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
    Miranda S; Martorell S; Costa M; Ferrer L; Ramis A
    Vet Parasitol; 2007 Mar; 144(3-4):251-60. PubMed ID: 17110042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCR follow-up examination after treatment of canine leishmaniosis (CaL).
    Steuber S; Moritz A; Schirrmann I; Greiner M
    Tokai J Exp Clin Med; 1998 Dec; 23(6):285-92. PubMed ID: 10622624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.